Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar, +11

Annals of Oncology

Liposomal Doxorubicin HclMetastatic Breast CancerOncologyBreast OncologyPharmacology +6

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson, +12

Journal of Clinical Oncology

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Peter Reichardt, Gϋnter von Minckwitz, Peter Thuss‐Patience, +9

Annals of Oncology

Metastatic Breast CancerOncologyBreast OncologyOral CapecitabineMedicine +5

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

Claire F. Verschraegen, Tally Levy, Andrzej P. Kudelka, +10

Journal of Clinical Oncology

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.

A P Kudelka, Tally Levy, Claire F. Verschraegen, +16

PubMed

Squamous Cell CancerRetinal HemorrhageCervical CancerWeight LossMedicine +12

Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion.

S M Rowe, Sean Coughlan, Neil J. McKenna, +4

PubMed

GeneticsGenetic EpidemiologyGermline Taqi RflpGynecologyPathology +17

Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50.

Shan Wang‐Gohrke, Jenny Chang‐Claude, Heiko Becher, +2

PubMed

Breast OncologyGeneticsReproductive HealthGenetic EpidemiologyGynecology +19

A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma

D G Kieback, D. N. Carney, M. D. Fanning, +1

British Journal of Cancer

Tumor BiologyProgesterone Receptor GeneHormonal ReceptorGynecologyPathology +6

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

Shan Wang‐Gohrke, W. Weikel, Harvey A. Risch, +13

British Journal of Cancer

Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer

Martin Oehler, Dagmar‐C. Fischer, Marzenna Orlowska‐Volk, +4

British Journal of Cancer

Adrenal GlandBreast OncologyAdm Peptide ExpressionMedicineImmunology +12